Focus Stocks
Amgen Is Close to its 50 Day Moving Average
Published on Wednesday, 12 September 2012 06:52 Written by TradersHuddle Wire
New York, September 12th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $83.94, near its 50 day moving average that is set at $80.89. Amgen's price action is just above this important support level, providing a trading opportunity.
Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The company concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
The peaks and troughs algorithm shows calculated support at $75.70 and calculated resistance at $85.28. These levels should also be evaluated when planning trades, as they provide an insight into the latest price action.
Traders wanting to establish a position on Amgen should look for evidence of buying near the 50 day moving average, and open this position as close as possible to this important level. Also, they need to consider the latest range defined by the peaks and troughs algorithm for insights on other key levels that might impact an upside or downside move.
Related Articles
- NASDAQ 100 Round Up - Flat: FSLR, CTRP, BIDU
- Reference Points for Amgen
- How to Play the Building Momentum in Amgen
- Trading Idea: Is Amgen close to Support?
- Amgen Is Close to the 50 Day Moving Average
- Amgen Is Close to its 50 Day Moving Average
- Amgen is Near a Key Support Area
- Is Amgen Close to Support?
- Reference Points for Amgen
- Amgen near Support
Related Partner Headlines
- Cramer's Top Stock Picks: AMGN, HPY, but Avoid JCP - TheStreet.com
- Amgen Stock To Go Ex-dividend Tomorrow (AMGN) - TheStreet.com
- Amgen Inc (AMGN): Today's Featured Drugs Winner - TheStreet.com
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial Did Not Meet Primary Endpoint - Benzinga
- Amgen Inc Stock Buy Recommendation Reiterated (AMGN) - TheStreet.com
- UPDATE: Oppenheimer Raises PT to $89 on Amgen - Benzinga
- UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Amgen - Benzinga
- Amgen's Third Quarter Earnings Report - Investopedia
- Analysts' Actions: CAT AMGN DNKN BTU COF - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,335.28 Trade time:4:36PM EDT Value change:▼19.12 (-0.12%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,666.29 Trade time:4:36PM EDT Value change:▼1.18 (-0.07%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,496.43 Trade time:5:15PM EDT Value change:▼2.54 (-0.07%)In The Wires
-
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings -
Equifax Adopts Attunity Replicate to Load Data Warehouse and Enable Big Data Analytics -
Getty Images to Explore Visual Storytelling and Future of Video at Cannes Lions 2013 -
Neusoft Becomes Industry Partner of the World Economic Forum -
Verrata™ Pressure Guide Wire and iFR® (Instant Wave-Free Ratio™) Software Modality will be on display at EuroPCR 2013[1] -
SAP to Work With Specialisterne to Employ People With Autism -
Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system -
GigaMedia's Cloud Business Hits New Strategic Milestone: Expansion Into Government Sector








